Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations. Janux is proud to have earned a 𝐆𝐫𝐞𝐚𝐭 𝐏𝐥𝐚𝐜𝐞 𝐓𝐨 𝐖𝐨𝐫𝐤 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧™ in 2024.